Revolutionary hair treatment could regrow 90% of lost hair – helping millions worldwide

Researchers from North Carolina State University have identified a microRNA (miRNA) that could promote hair regeneration. This miRNA – miR-218-5p – plays an important role in regulating the pathway involved in follicle regeneration, and could be a candidate for future drug development.

Hair loss affects millions of people worldwide, and while current treatments for hair loss can be costly and ineffective, ranging from invasive surgery to chemical treatments that don’t produce the desired result. Recent hair loss research indicates that hair follicles don’t disappear where balding occurs, they just shrink. If DP cells could be replenished at those sites, the follicles might recover.

A research team led by Ke Cheng, Randall B. Terry, Jr. Distinguished Professor in Regenerative Medicine at NC State’s College of Veterinary Medicine and professor in the NC State/UNC Joint Department of Biomedical Engineering, cultured DP cells both alone (2D) and in a 3D spheroid environment. A spheroid is a three-dimensional cellular structure that effectively recreates a cell’s natural microenvironment.

In a mouse model of hair regeneration, Cheng looked at how quickly hair regrew on mice treated with 2D cultured DP cells, 3D spheroid-cultured DP cells in a keratin scaffolding, and the commercial hair loss treatment Minoxidil. In a 20-day trial, mice treated with the 3D DP cells had regained 90% of hair coverage at 15 days.

“The 3D cells in a keratin scaffold performed best, as the spheroid mimics the hair microenvironment and the keratin scaffold acts as an anchor to keep them at the site where they are needed,” Cheng says.

The study’s findings indicate that the exosomes derived from the 3D spheroid-cultured DP cells contain miR-218-5p, a microRNA that enhances the molecular pathway responsible for promoting hair follicle growth. They found that increasing miR-218-5p promoted hair follicle growth, while inhibiting it caused the follicles to lose function.

Related Stories:

“Cell therapy with the 3D cells could be an effective treatment for baldness, but you have to grow, expand, preserve and inject those cells into the area,” Cheng says. “MiRNAs, on the other hand, can be utilized in small molecule-based drugs.

So potentially you could create a cream or lotion that has a similar effect with many fewer problems. Future studies will focus on using just this miRNA to promote hair growth.”

Hair loss is a common condition that affects millions of people worldwide, causing physical and psychological distress. While hair loss can occur for a variety of reasons, including genetics, hormonal changes, medications, and medical conditions, it can lead to feelings of insecurity and low self-esteem.

Research into hair loss treatments has been ongoing for many years, with a range of options available on the market, but there is still no cure for baldness.

Current treatments for hair loss include medications such as minoxidil and finasteride, which can be effective in slowing or halting hair loss, but they do not always result in regrowth. Hair transplant surgery is another option, but it is expensive and requires a skilled surgeon. Invasive surgical procedures can also be used, but they can be costly and pose risks such as scarring and infection.

The potential impact of this research is significant, as hair loss can have a profound impact on an individual's self-esteem and quality of life. By developing new and effective treatments for hair loss, researchers can improve the lives of millions of people worldwide.

The identification of miR-218-5p as a candidate for future drug development represents an important step forward in this area of research and provides hope for those affected by hair loss.

The next steps for researchers will be to conduct further studies to determine the safety and efficacy of miR-218-5p-based treatments for hair loss.

The research appears in Science Advances, and was supported by the National Institutes of Health and the American Heart Association. Cheng is corresponding author. Postdoctoral researcher Shiqi Hu is first author.

This study was performed, in part, at the Analytical Instrumentation Facility (AIF) at North Carolina State University, which is supported by the State of North Carolina and the NSF (award number ECCS-1542015).

This work made use of instrumentation at AIF acquired with the support from the NSF (DMR-1726294). The AIF is a member of the North Carolina Research Triangle Nanotechnology Network (RTNN), a site within the National Nanotechnology Coordinated Infrastructure (NNCI).

Note: Materials provided by The Brighter Side of News. Content may be edited for style and length.

Like these kind of feel good stories? Get the Brighter Side of News' newsletter.